{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:06:32Z","timestamp":1791925592754,"version":"4.3.4"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004787","name":"The Research Council","doi-asserted-by":"publisher","award":["RGP\/HSS\/19\/232\/2019"],"award-info":[{"award-number":["RGP\/HSS\/19\/232\/2019"]}],"id":[{"id":"10.13039\/501100004787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11033-021-06512-9","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T04:02:38Z","timestamp":1624852958000},"page":"5629-5645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Recent advances on drug development and emerging therapeutic agents for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"48","author":[{"given":"Teeba","family":"Athar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Al Balushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-3403","authenticated-orcid":false,"given":"Shah Alam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"6512_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1249\/JSR.0000000000000332","volume":"16","author":"SP Cass","year":"2017","unstructured":"Cass SP (2017) Alzheimer\u2019s disease and exercise: a literature review. Curr Sports Med Rep 16:19\u201322","journal-title":"Curr Sports Med Rep"},{"key":"6512_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0197-4580(98)00052-9","volume":"19","author":"NC Berchtold","year":"1998","unstructured":"Berchtold NC, Cotman CW (1998) Evolution in the conceptualization of dementia and Alzheimer\u2019s disease: Greco-Roman period to the 1960s. Neurobiol Aging 19:173\u2013189","journal-title":"Neurobiol Aging"},{"key":"6512_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","volume":"29","author":"PV Fish","year":"2019","unstructured":"Fish PV, Steadman D, Bayle ED, Whiting P (2019) New approaches for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett 29:125\u2013133","journal-title":"Bioorg Med Chem Lett"},{"key":"6512_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1533317520937542","author":"S Gupta","year":"2020","unstructured":"Gupta S, Nair A, Jhawat V, Mustaq N, Sharma A, Dhanawat M, Khan SA (2020) Unwinding complexities of diabetic Alzheimer by potent novel molecules, American. J Alzheimer\u2019s Dis Other Dementias. https:\/\/doi.org\/10.1177\/1533317520937542","journal-title":"J Alzheimer's Dis Other Dementias"},{"key":"6512_CR5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ijbiomac.2017.07.116","volume":"105","author":"TN Shamsi","year":"2017","unstructured":"Shamsi TN, Athar T, Parveen R, Fatima S (2017) A review on protein misfolding, aggregation and strategies to prevent related ailments. Int J Biol Macromol 105:993\u20131000","journal-title":"Int J Biol Macromol"},{"key":"6512_CR6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","volume":"43","author":"AM Saunders","year":"1993","unstructured":"Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PS, Pericak-Vance MA, Joo S, Rosi B, Gusella J, Crapper-MacLachlan D, Alberts M (1993) Association of apolipoprotein E allele \u03f54 with late-onset familial and sporadic Alzheimer\u2019s disease. Neurology 43:1467\u20131467","journal-title":"Neurology"},{"key":"6512_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.neuron.2010.10.013","volume":"68","author":"L Bertram","year":"2010","unstructured":"Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68:270\u2013281","journal-title":"Neuron"},{"key":"6512_CR8","doi-asserted-by":"publisher","first-page":"130618","DOI":"10.1016\/j.molstruc.2021.130618","volume":"241","author":"A Husain","year":"2021","unstructured":"Husain A, Al Balushi K, Akhtar MJ, Khan SA (2021) Coumarin linked heterocyclic hybrids: a promising approach to develop multi target drugs for Alzheimer\u2019s disease. J Mol Struct 241:130618","journal-title":"J Mol Struct"},{"key":"6512_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejmech.2014.01.020","volume":"75","author":"S Thiratmatrakul","year":"2014","unstructured":"Thiratmatrakul S, Yenjai C, Waiwut P, Vajragupta O, Reubroycharoen P, Tohda M, Boonyarat C (2014) Synthesis, biological evaluation and molecular modeling study of novel tacrine\u2013carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 75:21\u201330","journal-title":"Eur J Med Chem"},{"issue":"7","key":"6512_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","volume":"41","author":"O Benek","year":"2020","unstructured":"Benek O, Korabecny J, Soukup O (2020) A perspective on multi-target drugs for Alzheimer\u2019s disease. Trends Pharmacol Scie 41(7):434\u2013445","journal-title":"Trends Pharmacol Scie"},{"key":"6512_CR11","unstructured":"Ladostigil (2019)Therapeutics. https:\/\/www.alzforum.org\/therapeutics\/ladostigil Accessed on 4 March 2021"},{"key":"6512_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","volume":"232","author":"GL Snyder","year":"2015","unstructured":"Snyder GL, Vanover KE, Zhu H, Miller DB, O\u2019Callaghan JP, Tomesch J, Li P, Zhang Q, Krishnan V, Hendrick JP (2015) Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology 232:605\u2013621","journal-title":"Psychopharmacology"},{"key":"6512_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","volume":"319","author":"A Atri","year":"2018","unstructured":"Atri A, Fr\u00f6lich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL (2018) Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA 319:130\u2013142","journal-title":"JAMA"},{"issue":"4","key":"6512_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jiph.2020.10.012","volume":"14","author":"SA Khan","year":"2020","unstructured":"Khan SA, Al-Balushi K (2020) Combating COVID-19: the role of drug repurposing and medicinal plants. J Infection Public Health 14(4):495\u2013503","journal-title":"J Infection Public Health"},{"key":"6512_CR15","first-page":"1","volume":"14","author":"C Ballard","year":"2020","unstructured":"Ballard C, Aarsland D, Cummings J, O\u2019Brien J, Mills R, Molinuevo JL, Fladby T, Williams G, Doherty P, Corbett A (2020) Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol 14:1\u201313","journal-title":"Nat Rev Neurol"},{"key":"6512_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00662-x","volume":"12","author":"J Bauzon","year":"2020","unstructured":"Bauzon J, Lee G, Cummings J (2020) Repurposed agents in the Alzheimer\u2019s disease drug development pipeline. Alzheimer\u2019s Res Ther 12:1\u201316","journal-title":"Alzheimer's Res Ther"},{"key":"6512_CR17","first-page":"1","volume":"10","author":"N Kumar","year":"2020","unstructured":"Kumar N, Gahlawat A, Kumar RN, Singh YP, Modi G, Garg P (2020) Drug repurposing for Alzheimer\u2019s disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors. J Biomol Struct Dyn 10:1\u201315","journal-title":"J Biomol Struct Dyn"},{"key":"6512_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-191150","volume":"74","author":"M Ihara","year":"2020","unstructured":"Ihara M, Saito S (2020) Drug repositioning for Alzheimer\u2019s disease: finding hidden clues in old drugs. J Alzheimer\u2019s Dis 74:1\u201316","journal-title":"J Alzheimer's Dis"},{"key":"6512_CR19","doi-asserted-by":"crossref","first-page":"12095","DOI":"10.1002\/trc2.12095","volume":"6","author":"RJ Desai","year":"2020","unstructured":"Desai RJ, Varma VR, Gerhard T, Segal J, Mahesri M, Chin K, Nonnenmacher E, Gabbeta A, Mammen AM, Varma S (2020) Targeting abnormal metabolism in Alzheimer\u2019s disease: The Drug Repurposing for Effective Alzheimer\u2019s Medicines (DREAM) study. Alzheimer\u2019s Dementia 6:12095","journal-title":"Alzheimer's Dementia"},{"key":"6512_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s13311-014-0325-7","volume":"12","author":"T-W Kim","year":"2015","unstructured":"Kim T-W (2015) Drug repositioning approaches for the discovery of new therapeutics for Alzheimer\u2019s disease. Neurotherapeutics 12:132\u2013142","journal-title":"Neurotherapeutics"},{"key":"6512_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"A Corbett","year":"2012","unstructured":"Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C (2012) Drug repositioning for Alzheimer\u2019s disease. Nat Rev Drug Discov 11:833\u2013846","journal-title":"Nat Rev Drug Discov"},{"key":"6512_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","volume":"77","author":"R Howard","year":"2020","unstructured":"Howard R, Zubko O, Bradley R, Harper E, Pank L, O\u2019Brien J, Fox C, Tabet N, Livingston G, Bentham P (2020) Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol 77:164\u2013174","journal-title":"JAMA Neurol"},{"key":"6512_CR23","doi-asserted-by":"publisher","first-page":"e1002660","DOI":"10.1371\/journal.pmed.1002660","volume":"15","author":"B Lawlor","year":"2018","unstructured":"Lawlor B, Segurado R, Kennelly S, Olde Rikkert MG, Howard R, Pasquier F, B\u00f6rjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW (2018) Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial. PLoS Med 15:e1002660","journal-title":"PLoS Med"},{"key":"6512_CR24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-170101","volume":"61","author":"PG Kehoe","year":"2018","unstructured":"Kehoe PG, Blair PS, Howden B, Thomas DL, Malone IB, Horwood J, Clement C, Selman LE, Baber H, Lane A (2018) The rationale and design of the reducing pathology in Alzheimer\u2019s disease through Angiotensin TaRgeting (RADAR) Trial. J Alzheimers Dis 61:803\u2013814","journal-title":"J Alzheimers Dis"},{"key":"6512_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/cns.12116","volume":"19","author":"Y Song","year":"2013","unstructured":"Song Y, Chen X, Wang LY, Gao W, Zhu MJ (2013) Rho kinase inhibitor fasudil protects against \u03b2-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci Ther 19:603\u2013610","journal-title":"CNS Neurosci Ther"},{"key":"6512_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/mp.2012.163","volume":"19","author":"R Killick","year":"2014","unstructured":"Killick R, Ribe E, Al-Shawi R, Malik B, Hooper C, Fernandes C, Dobson R, Nolan P, Lourdusamy A, Furney S (2014) Clusterin regulates \u03b2-amyloid toxicity via Dickkopf-1-driven induction of the wnt\u2013PCP\u2013JNK pathway. Mol Psychiatry 19:88\u201398","journal-title":"Mol Psychiatry"},{"key":"6512_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-018-0231-6","volume":"8","author":"C Elliott","year":"2018","unstructured":"Elliott C, Rojo AI, Ribe E, Broadstock M, Xia W, Morin P, Semenov M, Baillie G, Cuadrado A, Al-Shawi R (2018) A role for APP in Wnt signalling links synapse loss with \u03b2-amyloid production. Transl Psychiatry 8:1\u201313","journal-title":"Transl Psychiatry"},{"key":"6512_CR28","first-page":"419","volume":"430","author":"S Santana","year":"2012","unstructured":"Santana S, Recuero M, Bullido MJ, Valdivieso F, Aldudo J (2012) Herpes simplex virus type I induces the accumulation of intracellular \u03b2-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells. Neurobiol Aging 430:419\u2013430","journal-title":"Neurobiol Aging"},{"key":"6512_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3233\/JAD-2010-101386","volume":"23","author":"R Lerchundi","year":"2011","unstructured":"Lerchundi R, Neira R, Valdivia S, Vio K, Concha MI, Zambrano A, Otth C (2011) Tau cleavage at D 421 by Caspase-3 is induced in neurons and astrocytes infected with herpes simplex virus type 1. J Alzheimers Dis 23:513\u2013520","journal-title":"J Alzheimers Dis"},{"key":"6512_CR30","first-page":"6940283","volume":"7","author":"RS Mahla","year":"2016","unstructured":"Mahla RS (2016) Stem cells applications in regenerative medicine and disease therapeutics. Int J Cell Biol 7:6940283","journal-title":"Int J Cell Biol"},{"key":"6512_CR31","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1093\/brain\/awy221","volume":"141","author":"L Lyon","year":"2018","unstructured":"Lyon L (2018) Stem cell therapies in neurology: the good, the bad and the unknown. Brain 141:e77\u2013e77","journal-title":"Brain"},{"key":"6512_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nbt.2565","volume":"31","author":"Y Liu","year":"2013","unstructured":"Liu Y, Weick JP, Liu H, Krencik R, Zhang X, Ma L, Zhou G-M, Ayala M, Zhang S-C (2013) Medial ganglionic eminence\u2013like cells derived from human embryonic stem cells correct learning and memory deficits. Nat Biotechnol 31:440\u2013447","journal-title":"Nat Biotechnol"},{"key":"6512_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/cr.2011.181","volume":"22","author":"X Liu","year":"2012","unstructured":"Liu X, Li F, Stubblefield EA, Blanchard B, Richards TL, Larson GA, He Y, Huang Q, Tan A-C, Zhang D (2012) Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res 22:321\u2013332","journal-title":"Cell Res"},{"key":"6512_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/YCO.0000000000000478","volume":"32","author":"S-M Wang","year":"2019","unstructured":"Wang S-M, Lee C-U, Lim HK (2019) Stem cell therapies for Alzheimer\u2019s disease: is it time? Curr Opin Psychiatry 32:105\u2013116","journal-title":"Curr Opin Psychiatry"},{"key":"6512_CR35","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/trf.12421","volume":"54","author":"RR Sharma","year":"2014","unstructured":"Sharma RR, Pollock K, Hubel A, McKenna D (2014) Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54:1418\u20131437","journal-title":"Transfusion"},{"key":"6512_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4252\/wjsc.v12.i8.787","volume":"12","author":"X-Y Liu","year":"2020","unstructured":"Liu X-Y, Yang L-P, Zhao L (2020) Stem cell therapy for Alzheimer\u2019s disease. World J Stem Cells 12:787","journal-title":"World J Stem Cells"},{"key":"6512_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/jpet.120.000324","volume":"377","author":"Z Si","year":"2021","unstructured":"Si Z, Wang X (2021) Stem cell therapies in Alzheimer\u2019s disease: applications for disease modeling. J Pharmacol Exp Ther 377:207\u2013217","journal-title":"J Pharmacol Exp Ther"},{"key":"6512_CR38","first-page":"1479","volume":"20","author":"K Sharma","year":"2019","unstructured":"Sharma K (2019) Cholinesterase inhibitors as Alzheimer\u2019s therapeutics. Mol Med Rep 20:1479\u20131487","journal-title":"Mol Med Rep"},{"key":"6512_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0143-4160(98)90115-4","volume":"23","author":"SA Lipton","year":"1998","unstructured":"Lipton SA, Nicotera P (1998) Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium 23:165\u2013171","journal-title":"Cell Calcium"},{"key":"6512_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C (2012) Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 366:893\u2013903","journal-title":"N Engl J Med"},{"key":"6512_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000008243","volume":"44","author":"M Farlow","year":"2000","unstructured":"Farlow M, Anand R, Messina J Jr, Hartman R, Veach J (2000) A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer\u2019s disease. Eur Neurol 44:236\u2013241","journal-title":"Eur Neurol"},{"key":"6512_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1750-3639.2005.tb00104.x","volume":"15","author":"TE Golde","year":"2005","unstructured":"Golde TE (2005) The A\u03b2 hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol 15:84\u201387","journal-title":"Brain Pathol"},{"key":"6512_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0896-6273(01)00475-5","volume":"32","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ (2001) Clearing the brain\u2019s amyloid cobwebs. Neuron 32:177\u2013180","journal-title":"Neuron"},{"key":"6512_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2015.10.005","volume":"588","author":"L Montoliu-Gaya","year":"2015","unstructured":"Montoliu-Gaya L, Villegas S (2015) Protein structures in Alzheimer\u2019s disease: the basis for rationale therapeutic design. Arch Biochem Biophys 588:1\u201314","journal-title":"Arch Biochem Biophys"},{"key":"6512_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000113713","volume":"5","author":"PT Francis","year":"2008","unstructured":"Francis PT (2008) Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer\u2019s disease. Neurodegener Dis 5:241\u2013243","journal-title":"Neurodegener Dis"},{"key":"6512_CR46","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/cmdc.201500216","volume":"10","author":"AK Ghosh","year":"2015","unstructured":"Ghosh AK, Tang J (2015) Prospects of \u03b2-secretase inhibitors for the treatment of Alzheimer\u2019s dishease. ChemMedChem 10:1463","journal-title":"ChemMedChem"},{"key":"6512_CR47","unstructured":"Hey J, Koelsch G, Bilcer G, Jacobs A, Tolar M, Tang J, Ghosh A, Hsu H (2008) Single dose administration of the \u03b2-secretase inhibitor CTS21166 (ASP1720) reduces plasma A\u03b240 in human subjects, International Conference on Alzheimer\u2019s Disease (ICAD)"},{"key":"6512_CR48","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3233\/JAD-150834","volume":"50","author":"S Eketj\u00e4ll","year":"2016","unstructured":"Eketj\u00e4ll S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, F\u00e4lting J, Haeberlein SB, Kugler AR, Alexander RC, Cebers G (2016) AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. J Alzheimers Dis 50:1109\u20131123","journal-title":"J Alzheimers Dis"},{"key":"6512_CR49","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1016\/S0140-6736(18)31425-9","volume":"391","author":"T Burki","year":"2018","unstructured":"Burki T (2018) Alzheimer\u2019s disease research: the future of BACE inhibitors. Lancet 391:2486","journal-title":"Lancet"},{"key":"6512_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fnagi.2018.00229","volume":"10","author":"T Blume","year":"2018","unstructured":"Blume T, Filser S, Jaworska A, Blain J-F, Koenig G, Moschke K, Lichtenthaler SF, Herms J (2018) BACE1 inhibitor MK-8931 alters formation but not stability of dendritic spines. Front Aging Neurosci 10:229","journal-title":"Front Aging Neurosci"},{"key":"6512_CR51","unstructured":"https:\/\/www.alzforum.org\/news\/research-news\/end-bace-inhibitors-elenbecestat-trials-halted-amid-safety-concerns. Accessed on 7 March 2021"},{"key":"6512_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0415-6","volume":"10","author":"M Timmers","year":"2018","unstructured":"Timmers M, Streffer JR, Russu A, Tominaga Y, Shimizu H, Shiraishi A, Tatikola K, Smekens P, B\u00f6rjesson-Hanson A, Andreasen N (2018) Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: randomized, double-blind, placebo-controlled study. Alzheimer\u2019s Res Therapy 10:1\u201318","journal-title":"Alzheimer's Res Therapy"},{"key":"6512_CR53","doi-asserted-by":"crossref","unstructured":"Koriyama Y, Hori A, Ito H, Yonezawa S, Baba Y, Tanimoto N, Ueno T, Yamamoto S, Yamamoto T, Asada N, Discovery of Atabecestat (JNJ-54861911) (2021) A thiazine-based \u03b2-amyloid precursor protein cleaving enzyme 1 inhibitor advanced to the phase 2b\/3 EARLY clinical trial, J Med Chem","DOI":"10.1021\/acs.jmedchem.0c01917"},{"key":"6512_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00614-5","volume":"12","author":"G Novak","year":"2020","unstructured":"Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, Russu A, Janssens L, Tesseur I, Tritsmans L (2020) Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer\u2019s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer\u2019s Res Therapy 12:1\u201316","journal-title":"Alzheimer's Res Therapy"},{"key":"6512_CR55","doi-asserted-by":"crossref","unstructured":"U. Neumann, M. Ufer, L.H. Jacobson, M.L. Rouzade\u2010Dominguez, G. Huledal, C. Kolly, R.M. L\u00fc\u00f6nd, R. Machauer, S.J. Veenstra, K. Hurth, The BACE\u20101 inhibitor CNP 520 for prevention trials in Alzheimer's disease, EMBO molecular medicine, 10 (2018) e9316.","DOI":"10.15252\/emmm.201809316"},{"key":"6512_CR56","unstructured":"https:\/\/www.novartis.com\/news\/media-releases\/novartis-amgen-and-banner-alzheimers-institute-discontinue-clinical-program-bace-inhibitor-cnp520-alzheimers-prevention. Accessed on 4 March 2021"},{"key":"6512_CR57","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.wnf.0000167360.27670.29","volume":"28","author":"E Siemers","year":"2005","unstructured":"Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC (2005) Safety, tolerability, and changes in amyloid \u03b2 concentrations after administration of a \u03b3-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126\u2013132","journal-title":"Clin Neuropharmacol"},{"key":"6512_CR58","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8501693","author":"J Folch","year":"2016","unstructured":"Folch J, Petrov D, Ettcheto M, Abad S, S\u00e1nchez-L\u00f3pez E, Garc\u00eda ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A (2016) Current research therapeutic strategies for Alzheimer\u2019s disease treatment. Neural Plast. https:\/\/doi.org\/10.1155\/2016\/8501693","journal-title":"Neural Plast"},{"key":"6512_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756285612461679","volume":"6","author":"KG Yiannopoulou","year":"2013","unstructured":"Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disord 6:19\u201333","journal-title":"Ther Adv Neurol Disord"},{"key":"6512_CR60","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40262-012-0005-x","volume":"51","author":"R Dockens","year":"2012","unstructured":"Dockens R, Wang J-S, Castaneda L, Sverdlov O, Huang S-P, Slemmon R, Gu H, Wong O, Li H, Berman RM (2012) A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet 51:681\u2013693","journal-title":"Clin Pharmacokinet"},{"key":"6512_CR61","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","volume":"69","author":"V Coric","year":"2012","unstructured":"Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G (2012) Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430\u20131440","journal-title":"Arch Neurol"},{"key":"6512_CR62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijge.2016.07.003","volume":"11","author":"H Coman","year":"2017","unstructured":"Coman H, Neme\u015f B (2017) New therapeutic targets in Alzheimer\u2019s disease. Int J Gerontol 11:2\u20136","journal-title":"Int J Gerontol"},{"key":"6512_CR63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuropharm.2012.11.009","volume":"67","author":"E Siopi","year":"2013","unstructured":"Siopi E, Llufriu-Dab\u00e9n G, Cho AH, Vidal-Lletj\u00f3s S, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2013) Etazolate, an \u03b1-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology 67:183\u2013192","journal-title":"Neuropharmacology"},{"key":"6512_CR64","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","volume":"83","author":"K Endres","year":"2014","unstructured":"Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, T\u00fcscher O, Fellgiebel A (2014) Increased CSF APPs-\u03b1 levels in patients with Alzheimer disease treated with acitretin. Neurology 83:1930\u20131935","journal-title":"Neurology"},{"key":"6512_CR65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.yexcr.2015.04.004","volume":"334","author":"X Chang","year":"2015","unstructured":"Chang X, Rong C, Chen Y, Yang C, Hu Q, Mo Y, Zhang C, Gu X, Zhang L, He W (2015) (\u2212)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer\u05f3 s disease model mice by upregulating neprilysin expression. Exp Cell Res 334:136\u2013145","journal-title":"Exp Cell Res"},{"key":"6512_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11596-020-2142-z","volume":"40","author":"J Bao","year":"2020","unstructured":"Bao J, Liu W, Zhou H-Y, Gui Y-R, Yang Y-H, Wu M-J, Xiao Y-F, Shang J-T, Long G-F, Shu X-J (2020) Epigallocatechin-3-gallate alleviates cognitive deficits in APP\/PS1 mice. Curr Med Sci 40:18\u201327","journal-title":"Curr Med Sci"},{"key":"6512_CR67","doi-asserted-by":"crossref","unstructured":"M. Ettcheto, A. Cano, P.R. Manzine, O. Busquets, E. Verdaguer, R.D. Castro-Torres, M.L. Garc\u00eda, C. Beas-Zarate, J. Olloquequi, C. Auladell, Epigallocatechin-3-Gallate (EGCG) improves cognitive deficits aggravated by an obesogenic diet through modulation of unfolded protein response in APPswe\/PS1dE9 mice, Molecular neurobiology, (2019) 1\u201314.","DOI":"10.1007\/s12035-019-01849-6"},{"key":"6512_CR68","unstructured":"https:\/\/www.alzforum.org\/therapeutics\/epigallocatechin-gallate-egcg, Accessed on 5 March 2021"},{"key":"6512_CR69","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","volume":"7","author":"GK Wilcock","year":"2008","unstructured":"Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA (2008) TPIS investigators, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer\u2019s disease: a randomised phase II trial. Lancet Neurol 7:483\u2013493","journal-title":"Lancet Neurol"},{"key":"6512_CR70","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","volume":"92","author":"E Muntimadugu","year":"2016","unstructured":"Muntimadugu E, Dhommati R, Jain A, Challa VGS, Shaheen M, Khan W (2016) Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer\u2019s disease. Eur J Pharm Sci 92:224\u2013234","journal-title":"Eur J Pharm Sci"},{"key":"6512_CR71","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/156720507781788882","volume":"4","author":"PS Aisen","year":"2007","unstructured":"Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D (2007) Alzhemed: a potential treatment for Alzheimer\u2019s disease. Curr Alzheimer Res 4:473\u2013478","journal-title":"Curr Alzheimer Res"},{"key":"6512_CR72","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","volume":"32","author":"JA Hey","year":"2018","unstructured":"Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhn\u00e1lek M, Jeremy YY, Tolar M (2018) Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs 32:849\u2013861","journal-title":"CNS Drugs"},{"key":"6512_CR73","unstructured":"https:\/\/www.greenvalleypharma.com\/En\/Index\/pageView\/catid\/48\/id\/28.html, Accessed on 5 March 2021"},{"key":"6512_CR74","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04520412"},{"key":"6512_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00678-3","volume":"12","author":"T Wang","year":"2020","unstructured":"Wang T, Kuang W, Chen W, Xu W, Zhang L, Li Y, Li H, Peng Y, Chen Y, Wang B (2020) A phase II randomized trial of sodium oligomannate in Alzheimer\u2019s dementia. Alzheimer\u2019s Res Therapy 12:1\u201310","journal-title":"Alzheimer's Res Therapy"},{"key":"6512_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1520-6","volume":"16","author":"M Sochocka","year":"2019","unstructured":"Sochocka M, Ochnik M, Sobczy\u0144ski M, Siemieniec I, Orzechowska B, Naporowski P, Leszek J (2019) New therapeutic targeting of Alzheimer\u2019s disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response-preliminary study. J Neuroinflam 16:1\u201316","journal-title":"J Neuroinflam"},{"key":"6512_CR77","first-page":"235","volume":"13","author":"P Szaniszlo","year":"2009","unstructured":"Szaniszlo P, German P, Hajas G, Saenz D, Kruzel M, Boldogh I (2009) New insights into clinical trial for colostrininTM in Alzheimer\u2019s disease. JNHA 13:235\u2013241","journal-title":"JNHA"},{"key":"6512_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-2004-6103","volume":"6","author":"A Bilikiewicz","year":"2004","unstructured":"Bilikiewicz A, Gaus W (2004) Colostrinin 1 (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer\u2019s disease. J Alzheimers Dis 6:17\u201326","journal-title":"J Alzheimers Dis"},{"key":"6512_CR79","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","volume":"120","author":"J Delrieu","year":"2012","unstructured":"Delrieu J, Ousset PJ, Caillaud C, Vellas B (2012) \u2018Clinical trials in Alzheimer\u2019s disease\u2019: immunotherapy approaches. J Neurochem 120:186\u2013193","journal-title":"J Neurochem"},{"key":"6512_CR80","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","volume":"12","author":"ER Siemers","year":"2016","unstructured":"Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R (2016) Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer\u2019s disease patients. Alzheimers Dement 12:110\u2013120","journal-title":"Alzheimers Dement"},{"key":"6512_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy 9:1\u201315","journal-title":"Alzheimer's Res Therapy"},{"key":"6512_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M (2020) Aducanumab, gantenerumab, BAN2401, and ALZ-801\u2014the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimer\u2019s Res Therapy 12:1\u201310","journal-title":"Alzheimer's Res Therapy"},{"key":"6512_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, Wang G, Bateman R (2019) Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimer\u2019s Res Therapy 11:1\u201312","journal-title":"Alzheimer's Res Therapy"},{"key":"6512_CR84","unstructured":"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease. Accessed on 10 June 2021"},{"key":"6512_CR85","unstructured":"Biogen completes submission of Biologics License Application to FDA for aducanumab as a treatment for Alzheimer\u2019s disease. http:\/\/media.biogen.com\/news-releases\/news-release-details\/biogen-completes-submission-biologics-license-application-fda. Accessed on 4 March 2021"},{"key":"6512_CR86","unstructured":"Aducanumab Decision Delayed for Three Months. https:\/\/www.alzforum.org\/news\/research-news\/aducanumab-decision-delayed-three-months. Accessed on 4 March 2021"},{"key":"6512_CR87","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, M\u00f6ller C, Tegerstedt K, Lord A, Laudon H, Sj\u00f6dahl J, S\u00f6derberg L, Spens E, Sahlin C, Waara ER (2015) The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis 43:575\u2013588","journal-title":"J Alzheimers Dis"},{"key":"6512_CR88","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03887455"},{"key":"6512_CR89","unstructured":"Initiation of new phase iii clinical study (ahead 3\u201345) of ban2401 preclinical (asymptomatic) alzheimer\u2019s disease. https:\/\/www.eisai.com\/news\/2020\/news202042.html. Accessed on 12 March 2021"},{"key":"6512_CR90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejmech.2015.10.018","volume":"107","author":"M Maqbool","year":"2016","unstructured":"Maqbool M, Mobashir M, Hoda N (2016) Pivotal role of glycogen synthase kinase-3: a therapeutic target for Alzheimer\u2019s disease. Eur J Med Chem 107:63\u201381","journal-title":"Eur J Med Chem"},{"key":"6512_CR91","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4088\/JCP.08m04606","volume":"70","author":"H Hampel","year":"2009","unstructured":"Hampel H, Ewers M, B\u00fcrger K, Annas P, M\u00f6rtberg A, Bogstedt A, Fr\u00f6lich L, Schr\u00f6der J, Sch\u00f6nknecht P, Riepe MW (2009) Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70:922\u2013931","journal-title":"J Clin Psychiatry"},{"key":"6512_CR92","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2174\/156720512802455386","volume":"9","author":"Z Cai","year":"2012","unstructured":"Cai Z, Zhao Y, Zhao B (2012) Roles of glycogen synthase kinase 3 in Alzheimer\u2019s disease. Curr Alzheimer Res 9:864\u2013879","journal-title":"Curr Alzheimer Res"},{"key":"6512_CR93","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","volume":"148","author":"E Beurel","year":"2015","unstructured":"Beurel E, Grieco SF, Jope RS (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 148:114\u2013131","journal-title":"Pharmacol Ther"},{"key":"6512_CR94","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2174\/1389450119666180820104723","volume":"20","author":"J Alam","year":"2019","unstructured":"Alam J, Sharma L (2019) Potential enzymatic targets in Alzheimer\u2019s: a comprehensive review. Curr Drug Targets 20:316\u2013339","journal-title":"Curr Drug Targets"},{"key":"6512_CR95","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","volume":"61","author":"GK Wilcock","year":"2018","unstructured":"Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ (2018) Potential of low dose leuco-methylthioninium bis (hydromethanesulphonate)(LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: Cohort analysis as modified primary outcome in a phase III clinical trial. J Alzheimers Dis 61:435\u2013457","journal-title":"J Alzheimers Dis"},{"key":"6512_CR96","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1016\/j.jmb.2018.08.010","volume":"430","author":"YK Al-Hilaly","year":"2018","unstructured":"Al-Hilaly YK, Pollack SJ, Rickard JE, Simpson M, Raulin A-C, Baddeley T, Schellenberger P, Storey JM, Harrington CR, Wischik CM (2018) Cysteine-independent inhibition of Alzheimer\u2019s disease-like paired helical filament assembly by leuco-methylthioninium (LMT). J Mol Biol 430:4119\u20134131","journal-title":"J Mol Biol"},{"key":"6512_CR97","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03446001"},{"key":"6512_CR98","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.1021\/acs.jmedchem.8b00610","volume":"61","author":"A Gandini","year":"2018","unstructured":"Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez CN, Zuccheri G, Miti A (2018) Tau-centric multitarget approach for Alzheimer\u2019s disease: development of first-in-class dual glycogen synthase kinase 3\u03b2 and tau-aggregation inhibitors. J Med Chem 61:7640\u20137656","journal-title":"J Med Chem"},{"key":"6512_CR99","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbr.2015.09.020","volume":"296","author":"T Maurice","year":"2016","unstructured":"Maurice T (2016) Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. Behav Brain Res 296:270\u2013278","journal-title":"Behav Brain Res"},{"key":"6512_CR100","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314934"},{"key":"6512_CR101","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neuropharm.2017.11.042","volume":"130","author":"LM Smith","year":"2018","unstructured":"Smith LM, Zhu R, Strittmatter SM (2018) Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer\u2019s model. Neuropharmacology 130:54\u201361","journal-title":"Neuropharmacology"},{"key":"6512_CR102","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2967\/jnumed.118.223867","volume":"60","author":"T Toyonaga","year":"2019","unstructured":"Toyonaga T, Smith LM, Finnema SJ, Gallezot J-D, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y (2019) In vivo synaptic density imaging with 11C-UCB-J detects treatment effects of saracatinib in a mouse model of Alzheimer disease. J Nucl Med 60:1780\u20131786","journal-title":"J Nucl Med"},{"key":"6512_CR103","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","volume":"76","author":"CH Van Dyck","year":"2019","unstructured":"Van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS (2019) Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial. JAMA Neurol 76:1219\u20131229","journal-title":"JAMA Neurol"},{"key":"6512_CR104","doi-asserted-by":"publisher","first-page":"e0195486","DOI":"10.1371\/journal.pone.0195486","volume":"13","author":"X Wang","year":"2018","unstructured":"Wang X, Smith K, Pearson M, Hughes A, Cosden ML, Marcus J, Hess JF, Savage MJ, Rosahl T, Smith SM (2018) Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy. PLoS ONE 13:e0195486","journal-title":"PLoS ONE"},{"key":"6512_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0588-4","volume":"10","author":"J-H Lee","year":"2020","unstructured":"Lee J-H, Liow J-S, Paul S, Morse CL, Haskali MB, Manly L, Shcherbinin S, Ruble JC, Kant N, Collins EC (2020) PET quantification of brain O-GlcNAcase with [18 F] LSN3316612 in healthy human volunteers. EJNMMI Res 10:1\u201312","journal-title":"EJNMMI Res"},{"key":"6512_CR106","doi-asserted-by":"crossref","unstructured":"D. Barthold, G. Joyce, W. Wharton, P. Kehoe, J. Zissimopoulos, The association of multiple anti-hypertensive medication classes with Alzheimer\u2019s disease incidence across sex, race, and ethnicity, PloS one, 13 (2018) e0206705.","DOI":"10.1371\/journal.pone.0206705"},{"key":"6512_CR107","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3233\/JAD-171119","volume":"62","author":"PG Kehoe","year":"2018","unstructured":"Kehoe PG (2018) The coming of age of the angiotensin hypothesis in Alzheimer\u2019s disease: progress toward disease prevention and treatment? J Alzheimers Dis 62:1443\u20131466","journal-title":"J Alzheimers Dis"},{"key":"6512_CR108","unstructured":"https:\/\/www.alzforum.org\/therapeutics\/telmisartan. Accessed on 12 March 2021"},{"issue":"4","key":"6512_CR109","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3233\/JAD-200393","volume":"75","author":"U Haditsch","year":"2020","unstructured":"Haditsch U, Roth T, Rodriguez L, Hancock S, Cecere T, Nguyen M, Arastu-Kapur S, Broce S, Raha D, Lynch CC (2020) Alzheimer\u2019s disease-like neurodegeneration in Porphyromonas gingivalis infected neurons with persistent expression of active gingipains. J Alzheimer\u2019s Dis 75(4):1361\u20131376","journal-title":"J Alzheimer's Dis"},{"key":"6512_CR110","doi-asserted-by":"publisher","first-page":"040578","DOI":"10.1002\/alz.040578","volume":"16","author":"D Raha","year":"2020","unstructured":"Raha D, Broce S, Haditsch U, Rodriguez L, Ermini F, Detke M, Kapur S, Hennings D, Roth T, Nguyen M (2020) COR388, a novel gingipain inhibitor, decreases fragmentation of APOE in the central nervous system of Alzheimer\u2019s disease patients: Human\/Human trials: Other. Alzheimer\u2019s Dementia 16:040578","journal-title":"Alzheimer's Dementia"},{"key":"6512_CR111","unstructured":"https:\/\/www.alzheimers.gov\/alzheimers\/clinical-trials\/gain-trial-cor388-alzheimers-disease. Accessed on 12 March 2021"},{"key":"6512_CR112","unstructured":"https:\/\/www.alzforum.org\/therapeutics\/atuzaginstat. Accessed on 9 March 2021"},{"key":"6512_CR113","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14283\/jpad.2018.45","volume":"6","author":"P Novak","year":"2019","unstructured":"Novak P, Zilka N, Zilkova M, Kovacech B, Skrabana R, Ondrus M, Fialova L, Kontsekova E, Otto M, Novak M (2019) AADvac1, an active immunotherapy for Alzheimer\u2019s disease and non Alzheimer Tauopathies: an overview of preclinical and clinical development. J Prev Alzheimer\u2019s Dis 6:63\u201369","journal-title":"J Prev Alzheimer's Dis"},{"key":"6512_CR114","doi-asserted-by":"publisher","first-page":"0222505","DOI":"10.1371\/journal.pone.0222505","volume":"14","author":"J Benito-Le\u00f3n","year":"2019","unstructured":"Benito-Le\u00f3n J, Contador I, Vega S, Villarejo-Galende A, Bermejo-Pareja F (2019) Non-steroidal anti-inflammatory drugs use in older adults decreases risk of Alzheimer\u2019s disease mortality. PLoS ONE 14:0222505","journal-title":"PLoS ONE"},{"issue":"4","key":"6512_CR115","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3233\/JAD-200466","volume":"76","author":"T Li","year":"2020","unstructured":"Li T, Martin E, Abada Y-S, Boucher C, C\u00e8s A, Youssef I, Fenaux G, Forand Y, Legrand A, Nachiket N (2020) Effects of chronic masitinib treatment in APPPS1dE9 transgenic mice modeling Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 76(4):1339\u20131345","journal-title":"J Alzheimer's Dis"},{"key":"6512_CR116","unstructured":"https:\/\/www.alzforum.org\/news\/research-news\/positive-phase-2-results-claimed-masitinib-alzheimers. Accessed on 9 March 2021"},{"key":"6512_CR117","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41582-019-0307-9","volume":"16","author":"G Erika","year":"2020","unstructured":"Erika G, M\u00fcnch G (2020) In search of an anti-inflammatory drug for Alzheimer disease. Nat Rev Neurol 16:131\u2013132","journal-title":"Nat Rev Neurol"},{"key":"6512_CR118","doi-asserted-by":"crossref","first-page":"149","DOI":"10.14283\/jpad.2018.18","volume":"5","author":"A Burstein","year":"2018","unstructured":"Burstein A, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L (2018) Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 5:149\u2013154","journal-title":"J Prev Alzheimer's Dis"},{"key":"6512_CR119","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02080364"},{"key":"6512_CR120","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1586\/14737175.2015.995639","volume":"15","author":"WJ Deardorff","year":"2015","unstructured":"Deardorff WJ, Shobassy A, Grossberg GT (2015) Safety and clinical effects of EVP-6124 in subjects with Alzheimer\u2019s disease currently or previously receiving an acetylcholinesterase inhibitor medication. Expert Rev Neurother 15:7\u201317","journal-title":"Expert Rev Neurother"},{"key":"6512_CR121","unstructured":"https:\/\/www.alzforum.org\/news\/research-news\/rare-severe-side-effects-sideline-some-phase-3-encenicline-trials. Accessed on 9 March 2021"},{"key":"6512_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt179","volume":"5","author":"M Prior","year":"2013","unstructured":"Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D (2013) The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer\u2019s disease mice. Alzheimer\u2019s Res Therapy 5:1\u201319","journal-title":"Alzheimer's Res Therapy"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06512-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06512-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06512-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T11:12:59Z","timestamp":1744110779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06512-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6512"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06512-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"28 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All authors have read and approved the manuscript prior to submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}